Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

Phase 3brepocitinibPositive

AI Analysis

Summary

Priovant announced the first patient enrollment in its Phase 3 BEACON+ study of brepocitinib for cutaneous sarcoidosis, following positive Phase 2 results and FDA Breakthrough Therapy Designation.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patients enrolled in Phase 3 BEACON+ study

Importance:6/10

Sentiment:

0.70

Phase 3Cutaneous SarcoidosisBreakthrough Therapy DesignationTrial Enrollment

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 11:00 AM

Read Original